Dr. Agarwal on the Efficacy of Intensified ADT in mHSPC

Partner | Cancer Centers | <b>Huntsman Cancer Institute at the University of Utah </b>

Neeraj Agarwal, MD, discusses the efficacy of intensified androgen deprivation therapy in patients with newly diagnosed, metastatic, hormone-sensitive prostate cancer.

Neeraj Agarwal, MD, professor of medicine, Presidential Endowed Chair of Cancer Research, director of Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute, University of Utah, discusses the efficacy of intensified androgen deprivation therapy (ADT) in patients with newly diagnosed, metastatic, hormone-sensitive prostate cancer (mHSPC).

Results from the randomized phase 3 SWOG S1216 trial (NCT01809691), which examined ADT plus TAK-700 vs ADT plus bicalutamide (Casodex) in patients with newly diagnosed mHSPC, showed that early intensification of ADT in combination with access to life-prolonging therapies approved in the metastatic castration-resistant prostate cancer (mCRPC) setting will likely result in improved overall survival (OS) benefits, according to Agarwal. Based on this benefit, moving forward, intensified ADT should be offered to all patients who are eligible for the approach, Agarwal concludes.